InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,570.64
(
-0.89%
)
US TECH 100
19,035.20
(
-1.37%
)
Dow Jones
40,712.78
(
-0.43%
)
Brent Oil
76.71
(
0.14%
)
Bitcoin
60,852.42
(
0.80%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

fmrick

Send PM Follow Ignore
Followers 15
Posts 734
Boards Moderated 0
Alias Born 05/30/2009

fmrick

Re: haiqi post# 51028

Tuesday, 05/24/2011 11:37:49 PM

Tuesday, May 24, 2011 11:37:49 PM

Post# of 58465

Survival in a Phase 3, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH) (AGENDA). Abstract #8531. Poster Session: Monday, June 6, 2011 8:00 AM-12:30 PM; Discussion Session 11:30 AM-12:30 PM.

this is the day !



Dude, I hope you are not pinning your hopes to that trial.

That is the FAILED Agenda trial.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up